Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Alembic Pharmaceuticals Limited is a pharmaceutical company engaged in developing formulations and active pharmaceutical ingredients (API).
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has almost stayed constant
1 day ago•Business Standard
3 days ago•Business Standard
4 days ago•Economic Times
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 24, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg". | Download
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 24, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg". | Download
Final • Div/Share: ₹ 11
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant